Announcement

Collapse
No announcement yet.

Ofatumumab outperforms Aubagio

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Ofatumumab outperforms Aubagio

    Ofatumumab outperforms Aubagio in a head to head clinical trial. This isn't a surprise since the average efficacy of Aubagio is in line with the CRAB drugs and Arzerra in line with Rituximab or Ocrelizumab.

    Expect Ofatumumab to be approved this fall.

    https://multiplesclerosisnewstoday.c...ple-sclerosis/
Working...
X